Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma: Chemoradiotherapy in esophageal cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“because paclitaxel/carbotaxol has been described less toxic compared with cisplatinum/5‐FU.42”
From Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment (2020) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Law, S., Fok, M., Chow*, S., Chu, K.-M., & Wong, J. (1997) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(97)70147-8 · Cited by 381
Research works printed but not linked: 23
- Devesa, 1998, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States, Cancer, 83, 2049, 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2 · DOI · Paper page
- Pohl, 2005, The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence, J Natl Cancer Inst, 97, 142, 10.1093/jnci/dji024 · DOI · Paper page
- Hulscher, 2002, Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus, N Engl J Med, 347, 1662, 10.1056/NEJMoa022343 · DOI · Paper page
- Sjoquist, 2011, Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol, 12, 681, 10.1016/S1470-2045(11)70142-5 · DOI · Paper page
- Ajani, 2008, Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen, Cancer, 113, 945, 10.1002/cncr.23661 · DOI
- Minsky, 2002, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy, J Clin Oncol, 20, 1167, 10.1200/JCO.20.5.1167 · doi:10.1200/jco.20.5.1167 · Paper page
- Hagen, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 2074, 10.1056/NEJMoa1112088 · DOI · Paper page
- Heijl, 2008, Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS), BMC Surg, 8, 21, 10.1186/1471-2482-8-21 · DOI
- Trotti, 2003, CTCAE V3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Semin Radiat Oncol, 13, 176, 10.1016/S1053-4296(03)00031-6 · DOI · Paper page
- Sobin, 2002, International Union against Cancer. TNM: Classification of Malignant Tumours
- Chirieac, 2005, Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation, Cancer, 103, 1347, 10.1002/cncr.20916 · DOI · Paper page
- Ancona, 2001, Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone, Cancer, 91, 2165, 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H · DOI · Paper page
- Burmeister, 2005, Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial, Lancet Oncol, 6, 659, 10.1016/S1470-2045(05)70288-6 · DOI · Paper page
- Burmeister, 2011, Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial, Eur J Cancer, 47, 354, 10.1016/j.ejca.2010.09.009 · DOI · Paper page
- Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531 · DOI · Paper page
- Walsh, 1996, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma, N Engl J Med, 335, 462, 10.1056/NEJM199608153350702 · DOI · Paper page
- Ychou, 2011, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin Oncol, 29, 1715, 10.1200/JCO.2010.33.0597 · DOI · Paper page
- Herskovic, 1992, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 326, 1593, 10.1056/NEJM199206113262403 · DOI · Paper page
- Meerten, 2006, Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study, Br J Cancer, 94, 1389, 10.1038/sj.bjc.6603134 · DOI
- Bosset, 1997, Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N Engl J Med, 337, 161, 10.1056/NEJM199707173370304 · DOI · Paper page
- Lee, 2004, A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma, Ann Oncol, 15, 947, 10.1093/annonc/mdh219 · DOI · Paper page
- Stahl, 2009, Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction, J Clin Oncol, 27, 851, 10.1200/JCO.2008.17.0506 · DOI · Paper page
- Gebski, 2007, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis, Lancet Oncol, 8, 226, 10.1016/S1470-2045(07)70039-6 · DOI · Paper page
Cited by
Liu, J., Yang, Y., Liu, Z., Fu, X., Cai, X., Li, H., Zhu, L., Shen, Y., Zhang, H., Sun, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004291 · Cited by 282
Hagens, E. R. C., Feenstra, M. L., van Egmond, M. A., van Laarhoven, H. W. M., Hulshof, M. C. C. M., Boshier, P. R., Low, D. E., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12540 · Cited by 65
Self-citation
Metadata
- Authors
- Blom, R. L. G. M., Sosef, M. N., Nap, M., Lammering, G., van den Berkmortel, F., Hulshof, M. C. C. M., Meijer, S. L., Wilmink, H. W., & van Berge Henegouwen, M. I.
- Affiliations
- Department of Surgery; Academic Medical Center; Amsterdam
- Department of Surgery; Atrium Medical Center; Heerlen
- Department of Pathology; Atrium Medical Center; Heerlen
- Department of Radiation Oncology; MAASTRO; Maastricht the Netherlands
- Department of Internal Medicine and Gastroenterology; Academic Medical Center; Amsterdam
- Department of Radiation Oncology; Academic Medical Center; Amsterdam
- Department of Pathology; Academic Medical Center; Amsterdam
- Department of Medical Oncology; Academic Medical Center; Amsterdam
- Venue
- Diseases of the Esophagus
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-05
- Volume
- 27
- Issue
- 4
- Pages
- 380-387
- ISSN
- 1120-8694
- Cited by
- 39
- References
- 1
- Language
- en
- Licence
- doi.wiley.com/10.1002/tdm_license_1 (tdm, 726 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma: Chemoradiotherapy in esophageal cancer. https://app.cochat.ai/papers/10.1111/dote.12110
- The paper
- Blom, R. L. G. M., Sosef, M. N., Nap, M., Lammering, G., van den Berkmortel, F., Hulshof, M. C. C. M., Meijer, S. L., Wilmink, H. W., & van Berge Henegouwen, M. I. (2014). Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma: Chemoradiotherapy in esophageal cancer. Diseases of the Esophagus. https://doi.org/10.1111/dote.12110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.